Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Asset Writedowns and Impairment (2024)

Avanos Medical (AVNS) has disclosed Asset Writedowns and Impairment for 1 consecutive years, with $336.5 million as the latest value for Q4 2024.

  • Quarterly Asset Writedowns and Impairment changed N/A to $336.5 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $336.5 million through Dec 2024, changed N/A year-over-year, with the annual reading at $77.0 million for FY2025, 82.37% down from the prior year.
  • Asset Writedowns and Impairment hit $336.5 million in Q4 2024 for Avanos Medical.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $336.5 million in Q4 2024 to a low of $336.5 million in Q4 2024.